Six years ago Abiraterone was hailed as a medical breakthrough that could offer men extra time with loved ones and a chance to delay chemotherapy and its debilitating side effects.
Today the body that recommends what can and cannot be paid for said it 'wasn't cost effective'.
Prostate cancer patients have now been told that the life-extending drug will not be routinely prescribed unless they have chemotherapy.
One man from North Yorkshire who is fighting prostate cancer is calling for a rethink:
More top news
It was always going to be a very mild one, with a warm pocket of air travelling over the UK for Halloween - but it's now the warmest ever!
Your pictures of carved pumpkins this Halloween
Weather update with Kerrie Gosney.